CA
BCRX icon

Continuum Advisory’s BioCryst Pharmaceuticals BCRX Stock Holding History

Continuum Advisory’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,668
Closed -$12.5K – 517
2025
Q1 		$12.5K Buy
1,668
+470
+39% +$3.79K ﹤0.01% 934
2024
Q4 		$9.01K Sell
1,198
-91
-7% -$691 ﹤0.01% 1016
2024
Q3 		$9.6K Buy
1,289
+91
+8% +$692 ﹤0.01% 1004
2024
Q2 		$7.4K Hold
1,198
– – ﹤0.01% 1015
2024
Q1 		$6.4K Buy
+1,198
New +$6.74K ﹤0.01% 1031

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Continuum Advisory's BCRX Position: Q2 2025 in Review

Continuum Advisory sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2025, closing a stake of 1,668 shares — an estimated $12.5K sold.

Continuum Advisory first reported a position in BCRX in Q1 2024 and held it in 5 quarters. The position peaked at $12.5K in Q1 2025. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

  • Continuum Advisory reported no remaining BioCryst Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 1,668 BioCryst Pharmaceuticals shares in Q2 2025, an estimated $12.5K.
  • Continuum Advisory first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's BioCryst Pharmaceuticals position peaked at $12.5K in Q1 2025.
  • 294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.